Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085247 | 0.85 | CA2 (0.41) | CA1CA2CA7CA13 | |
| SCHEMBL4445189 | 0.74 | USP2 (0.54) | USP2TSHRCA1CA2 | |
| SCHEMBL4245730 | 0.74 | F2 (0.33) | CA1CA2CA7CA13 | |
| SCHEMBL2572923 | 0.74 | USP2 (0.35) | USP2TSHRCA1CA2CA7 | |
| SCHEMBL2721777 | 0.73 | CA1 (0.37) | CA1CA2CA7CA13 | |
| SCHEMBL28396077 | 0.72 | CA2 (0.56) | TSHRCA1CA2CA7CA13 | |
| SCHEMBL29101966 | 0.72 | USP2 (0.33) | USP2TSHRCA1CA2CA7 | |
| SCHEMBL28116493 | 0.71 | USP2 (0.50) | USP2TSHRCA1CA2 | |
| SCHEMBL1345425 | 0.71 | CA1 (0.35) | CA1CA2CA7CA13 | |
| SCHEMBL29162625 | 0.70 | CA1 (0.30) | CA1CA2CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895570-B2 | Purine derivatives | ASTRAZENECA AB (SE) | 2014-11-25 | — | — | US | disclosed |
| US-20130338174-A1 | PURINE DERIVATIVES | Sumitomo Pharma Co., Ltd. (JP) | 2013-12-19 | — | — | US | disclosed |
| EP-2651943-A1 | PURINE DERIVATIVES | Astrazeneca AB (SE) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080730-A1 | PURINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338174-A1 | PURINE DERIVATIVES | HPRT1, PNP, SLC29A1 | USP2 4810/4885TSHR 3638/4885CA1 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.